No data available.
Please log in to see this content.
You have no subscription access to this content.
The full text of this article is not currently available.
Phase II Study of 24-Hour Infusion of Paclitaxel(Intaxel)with Carboplatin in Advanced Non-Small Cell Lung Cancer
Rent:
Rent this article for
JPY
Abstract
Purpose: To determine the activity and toxicity of combined 24-hour infusion of paclitaxel with carboplatin in advanced non-small cell lung cancer. Patients and Methods: Eligibility required measurable disease; stage IIIB with malignant pleural effusion or stage IV disease, with a performance status(PS)of ECOG 0-2. Chemotherapy consisted of 24 hours continuous infusion of paclitaxel at 135 mg/m2 on day 1, followed by carboplatin(AUC=6)on day 2.Treatment was repeated at 3-week intervals for a total of 6 cycles. Results: Thirty-nine patients were enrolled. Twenty six patients were male and 13 female, with a median age of 57 years(range, 38 to 72). Six patients(15%)had stage IIIB and 33(85%)had stage IV. PS 0-1/2 was 67%/33%. A total of 131 cycles was administered and the median number of cycles was 4(range, 2-6). Grade 3-4 neutropenia, grade 3-4 leukopenia and grade 3 anemia occurred in 3%, 3% and23%, respectively. One patient(3%)developed febrile neutropenia. Grade 3 diarrhea occurred in 3 patients(8%). Other non-hematologic toxicities were mild including mucositis and skin rash. The overall response rate was 15%. Median survival was 8 months(range 6-9.5 months)and 1-year survival rate was 20%. Conclusions: The combined 24-hour infusion of paclitaxel(Intaxel)with carboplatin is a feasible and well-tolerated regimen in the treatment of advancedNSCLC patients. Key words: paclitaxel, carboplatin, non-small cell lung cancer(Received Fed. 19, 2007/Accepted Mar. 23, 2007)
Full text loading...
/content/article/0385-0684/34100/1603